Proactive Investors - Run By Investors For Investors

AusCann Group Holdings' receipt of cannabis oils from Canopy Growth is imminent

A collaborative distribution agreement would see the two parties selling both their products into the Australian market.
Medicinal cannabis
The company will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation

Auscann Group Holdings Limited (ASX:AC8), a leading medical cannabis company, has received an import permit under its existing import licence.

Following this development, the company will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation.

AusCann and Canopy Growth are pursuing opportunities in several key areas in Australia including the importation, distribution and local production of medical cannabis products.

AusCann managing director Elaine Darby said: “Our ongoing relationship with Canopy Growth offers major benefits for AusCann and we are very pleased to be working with Canopy Growth as the Australian market expands.

“The combination of this arrangement and our strong partnership with Tasmanian Alkaloids, positions us to be the leading supplier of affordable, effective and clinically-validated cannabinoid medicines to the Australian market and select international markets.”

AusCann's vertically integrated business model

Initial import of pain relief products

AusCann will initially import the Canopy Growth-supplied AusCann branded products for chronic and neuropathic pain control known as AC 5:5, AC 0:9.5 and AC 15:0.

Each name represents the ratio of tetrahydrocannabinol (THC) to cannabidiol (CBD) in each product.

Potential distribution of Spectrum Cannabis

Canopy Growth and AusCann are working together on developing an arrangement whereby the former will also supply AusCann with its Spectrum Cannabis branded products.

This would see AusCann distributing the product into the Australian market alongside existing AusCann products.

Spectrum Cannabis is Canopy Growth’s international medical brand, operating under a simple colour-coded system to classify its medical cannabis products.

Cashing in on distribution network

The intention is for both parties to undertake the distribution of AusCann and Spectrum products through existing and future distribution networks.

This includes AusCann’s extensive distribution network, recently broadened through the establishment of a relationship with Australian Pharmaceutical Industries (ASX:API).

READ: Auscann Group Holdings to access large Australian pharmaceutical network

Australian Pharmaceutical Industries has a network of 466 high profile brand pharmacies with representation in every state and territory in Australia.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

November 01 2018
The 35,000 sq ft automated facility is equipped with proprietary fertigation, operational and security systems
A cannabis facility
December 02 2018
The Vancouver-based medicinal cannabis grower’s Queensland facility will be the world's largest greenhouse cannabis operation, covering a 99-acre site
October 31 2018
The firm wants to become the first publicly listed, globally focused, pure cannabis company

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use